GILD
NASD Gilead Sciences, Inc.$152.32 ↑ +1.89 (+1.26%) Trading Up from the previous close of $150.43, and at the day’s high of $152.26
- YTD change
- +24.10%
- vs 20-day SMA
- +2.39%
- vs 200-day SMA
- +10.93%
Price ranges
Price & Performance
+11.40 (+8.20%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 3.2% away from all-time highs of $157.29
- GILD is up 24% since the beginning of the year
- GILD is up 30% over the past 12 months
- GILD is up 6% over the past 1 month
- 2% of all GILD investors are betting against GILD
GILD reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +27.3%.
- Previous minute
- +$0.53
- Last hour
- +$1.68
- Last 5 days
- +5.24%
- vs 8-day SMA
- +3.68%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
